DK2800574T3 - Antiinflammatoriske sammensætninger med malvidin-3-0-beta glucosid og et Propolis-ekstrakt - Google Patents

Antiinflammatoriske sammensætninger med malvidin-3-0-beta glucosid og et Propolis-ekstrakt Download PDF

Info

Publication number
DK2800574T3
DK2800574T3 DK12756729.5T DK12756729T DK2800574T3 DK 2800574 T3 DK2800574 T3 DK 2800574T3 DK 12756729 T DK12756729 T DK 12756729T DK 2800574 T3 DK2800574 T3 DK 2800574T3
Authority
DK
Denmark
Prior art keywords
weight
extract
composition according
composition
propolis
Prior art date
Application number
DK12756729.5T
Other languages
English (en)
Inventor
M Djavad Mossalyai
Jean-Michel Merillon
Loa C Renard
Original Assignee
Univ Bordeaux
Nutrivercell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bordeaux, Nutrivercell filed Critical Univ Bordeaux
Application granted granted Critical
Publication of DK2800574T3 publication Critical patent/DK2800574T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L21/00—Marmalades, jams, jellies or the like; Products from apiculture; Preparation or treatment thereof
    • A23L21/20—Products from apiculture, e.g. royal jelly or pollen; Substitutes therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A61K35/644—Beeswax; Propolis; Royal jelly; Honey
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Insects & Arthropods (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (17)

1. Antiinflammatorisk sammensætning, omfattende a. et planteekstrakt med mindst 5 vægt%, fortrinsvis fra 5 til 20 vægt%, fordelagtigt fra 5 til 15 vægt% malvidin-3-0-p-glucosid; og b. et ekstrakt af Propolis med coffeinsyre eller en ester deraf, ferulasyre, galangin og pinocembrin; i et vægtforhold a/b planteekstrakt/P ropol is-ekstrakt, som går fra 1/4 til 4/1.
2. Sammensætning ifølge krav 1, som er i fast form eller flydende form, eller hvor planteekstrakten er et vindrueskalekstrakt, som opnås eller kan opnås med en fremgangsmåde, der omfatter koncentration af de polyphenoliske fraktioner af mindst én rød vindruekvas.
3. Sammensætning ifølge de foregående krav, omfattende - fra 0,1 til 50 vægt%, fortrinsvis fra 1 til 40 vægt%, planteekstrakt, eller - fra 20 til 80 vægt%, fortrinsvis fra 30 til 70 vægt%, Propolis-ekstrakt, eller - fra 0,1 til 50 vægt%, fortrinsvis fra 1 til 40 vægt%, planteekstrakt og fra 20 til 80 vægt%, fortrinsvis fra 30 til 70 vægt% Propolis-ekstrakt.
4. Sammensætning ifølge de foregående krav, hvor Propolis-ekstraktet omfatter • fra 0,001 til 0,2 vægt%, fortrinsvis fra 0,005 til 0,15 vægt% coffeinsyre eller en ester deraf; • fra 0,0001 til 0,005 vægt%, fortrinsvis fra 0,0005 til 0,003 vægt% ferulasyre; • fra mellem 0,05 til 10 vægt%, fortrinsvis fra 0,1 til 6 vægt% galangin; • fra 0,1 til 5 vægt%, fortrinsvis fra 0,2 til 3 vægt% pinocembrin;
5. Sammensætning ifølge de foregående krav, ligeledes omfattende capsaicin eller et antiinflammatorisk middel eller en blanding deraf.
6. Sammensætning ifølge det foregående krav, omfattende fra 0,01 til 0,1 vægt%, fortrinsvis fra 0,025 til 0,075 vægt% capsaicin.
7. Sammensætning ifølge et hvilket som helst af de foregående krav, ligeledes omfattende en fødevareingrediens.
8. Sammensætning ifølge det foregående krav, hvor fødevareingrediensen er udvalgt blandt piperin eller et zinkderivat.
9. Sammensætning ifølge krav 7 eller 8, omfattende fra 0,01 til 4 vægt%, fortrinsvis fra 0,1 til 1 vægt% piperin.
10. Sammensætning ifølge krav 7 eller 8, omfattende fra 0,01 til 2 vægt%, fortrinsvis fra 0,1 til 1,5 vægt% zinkderivat.
11. Kosttilskud, omfattende en sammensætning ifølge et hvilket som helst af krav 1 til 10.
12. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, i form af en topisk sammensætning.
13. Sammensætning ifølge krav 12, til anvendelse i behandlingen eller forebyggelsen af akutte eller kroniske betændelsessygdomme, især til behandlingen eller forebyggelsen af leddegigt.
14. Sammensætning ifølge et hvilket som helst af krav 1 til 6, der er beregnet til anvendelse som medikament.
15. Sammensætning ifølge et hvilket som helst af kravene 1 til 6, til anvendelse i behandlingen eller forebyggelsen af akutte eller kroniske betændelsessygdomme, især til behandlingen eller forebyggelsen af leddegigt.
16. Kit, omfattende - en første sammensætning ifølge et hvilket som helst af kravene 1 til 6, - en anden sammensætning, omfattende et antiinflammatorisk middel.
17. Fremgangsmåde til fremstilling af en sammensætning ifølge kravene 2 til 10, omfattende (i) fremstilling af et ekstrakt af vindrueskal, der opnås med udvælgelsen af mindst én rød vindruekvas og koncentration af de polyphenoliske fraktioner af kvasen, (ii) blanding af ekstrakten fra (i) og et Propolis-ekstrakt.
DK12756729.5T 2011-09-08 2012-09-07 Antiinflammatoriske sammensætninger med malvidin-3-0-beta glucosid og et Propolis-ekstrakt DK2800574T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1157995A FR2979826B1 (fr) 2011-09-08 2011-09-08 Composition anti-inflammatoire
PCT/EP2012/067584 WO2013034746A1 (fr) 2011-09-08 2012-09-07 Compositions anti - inflammatoires comprenant de la malvidine - 3 - o - beta glucoside et un extrait de propolis

Publications (1)

Publication Number Publication Date
DK2800574T3 true DK2800574T3 (da) 2017-09-25

Family

ID=46829763

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12756729.5T DK2800574T3 (da) 2011-09-08 2012-09-07 Antiinflammatoriske sammensætninger med malvidin-3-0-beta glucosid og et Propolis-ekstrakt

Country Status (10)

Country Link
US (1) US9308231B2 (da)
EP (1) EP2800574B1 (da)
JP (1) JP6043795B2 (da)
BR (1) BR112014005413B8 (da)
CA (1) CA2848009C (da)
DK (1) DK2800574T3 (da)
ES (1) ES2646444T3 (da)
FR (1) FR2979826B1 (da)
PL (1) PL2800574T3 (da)
WO (1) WO2013034746A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6708376B2 (ja) * 2015-07-10 2020-06-10 株式会社山田養蜂場本社 ＩＦＮ−γ及び／又はＩＬ−１７の産生抑制剤、並びにＴｈ１細胞及び／又はＴｈ１７細胞の分化抑制剤

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2946452B2 (ja) * 1994-11-04 1999-09-06 カディラ ラボラトリーズ リミテッド ピペリンを含む組成物
JP2003192603A (ja) * 2001-12-27 2003-07-09 National Institute Of Advanced Industrial & Technology 抗ガン剤および健康食品
JP2003238422A (ja) * 2002-02-12 2003-08-27 Toyo Shinyaku:Kk アポトーシス誘導剤および健康食品
WO2003075824A2 (en) * 2002-03-08 2003-09-18 Modi, Rajiv, Indravadan Process of manufacturing pharmaceutical composition useful for management of tuberculosis
CN1738632A (zh) * 2003-01-30 2006-02-22 科学与工业研究委员会 葛缕子提取物及其部分的生物利用度增强活性
JP2005001998A (ja) * 2003-06-09 2005-01-06 Api Co Ltd 血圧降下剤及びその製造方法、並びにプロポリス組成物及び食品製剤
RU2367464C2 (ru) * 2004-02-19 2009-09-20 Берингер Ингельхайм Интернациональ Гмбх Состав для лечения хронических венозных недостаточностей, содержащий водный экстракт листьев красного винограда и противовоспалительное средство
CN1994357A (zh) * 2005-12-31 2007-07-11 王凯 蓝莓与蜂胶配伍的提高免疫力的组合物
FR2916141B1 (fr) * 2007-05-15 2009-11-13 Univ Victor Segalen Bordeaux 2 Activite anti-polyarthrite rhumatoide de la malvidine -3-o-beta-glucoside in vivo.
FR2949197B1 (fr) 2009-08-21 2012-08-03 Loic Renard Composition alimentaire antibacterienne

Also Published As

Publication number Publication date
US9308231B2 (en) 2016-04-12
CA2848009C (fr) 2020-12-29
EP2800574B1 (fr) 2017-08-09
FR2979826A1 (fr) 2013-03-15
WO2013034746A1 (fr) 2013-03-14
CA2848009A1 (fr) 2013-03-14
BR112014005413B8 (pt) 2021-12-14
JP6043795B2 (ja) 2016-12-14
ES2646444T3 (es) 2017-12-13
FR2979826B1 (fr) 2013-12-27
BR112014005413B1 (pt) 2021-08-03
BR112014005413A2 (pt) 2017-04-04
US20140314888A1 (en) 2014-10-23
EP2800574A1 (fr) 2014-11-12
PL2800574T3 (pl) 2018-01-31
JP2014526451A (ja) 2014-10-06

Similar Documents

Publication Publication Date Title
Vetal et al. Anti-inflammatory and anti-arthritic activity of type-A procyanidine polyphenols from bark of Cinnamomum zeylanicum in rats
Bao et al. Genkwanin ameliorates adjuvant-induced arthritis in rats through inhibiting JAK/STAT and NF-κB signaling pathways
Pallarès et al. Grape seed procyanidin extract reduces the endotoxic effects induced by lipopolysaccharide in rats
JP5331962B2 (ja) 炎症性疾患のための薬草組成物
Tamashiro Filho et al. Evaluation of antiulcer activity and mechanism of action of methanol stem bark extract of Lafoensia pacari A. St.-Hil.(Lytraceae) in experimental animals
Pirouzpanah et al. The effect of chamomile tea consumption on inflammation among rheumatoid arthritis patients: randomized clinical trial
Martin et al. Aronia berry (Aronia mitschurinii ‘Viking’) inhibits colitis in mice and inhibits T cell tumour necrosis factor-α secretion
Liu et al. Studies on the cell-immunosuppressive mechanism of Oridonin from Isodon serra
Yang et al. Nobiletin mitigates NAFLD via lipophagy and inflammation
Khongrum et al. Antidyslipidemic, Antioxidant, and Anti‐inflammatory Effects of Jelly Drink Containing Polyphenol‐Rich Roselle Calyces Extract and Passion Fruit Juice with Pulp in Adults with Dyslipidemia: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Nisar et al. Modulation of T-helper cytokines and inflammatory mediators by Atropa accuminata. Royle in adjuvant induced arthritic tissues
EA023717B1 (ru) Применение композиции для понижающей регуляции/ингибирования pge2
Islam et al. Antidiarrheal activity of Dillenia indica bark extract
DK2800574T3 (da) Antiinflammatoriske sammensætninger med malvidin-3-0-beta glucosid og et Propolis-ekstrakt
Uahomo et al. Antidiarrheal Properties of Aqueous leaf extract of Cyathula prostrata on Castor oil-induced Diarrhoea in Wistar Rats
Wang et al. Cichoric acid from extracted Echinacea purpurea induces the proliferation and apoptosis of peripheral blood mononuclear cells from yaks
Rai et al. Anti–oxidation actions of curcumin in two forms of bed rest: oxidative stress serum and salivary markers
KR101179966B1 (ko) 항염증 효과를 갖는 관절염 치료를 위한 약제학적 조성물
PT1931366E (pt) Composição herbal para desordens inflamatórias
Lee et al. Anti-arthritis effect of mangostins from G. Mangostana
Zhou et al. Effects of fluoride on expression of cytokines in the hippocampus of adult rats
Bilal et al. Development of herbal formulation of medicinal plants and determination of its antihyperuricemic potential in vitro and in vivo rat's model.
Tiwari et al. Evaluation of antiulcer and antianxiety activity of Aphanmixis polystachya stem bark extract on rats
KR101332824B1 (ko) 민대극 추출물을 포함하는 관절염 예방 및 치료용 조성물
KR100973037B1 (ko) 사우치논 또는 사우치논을 함유하는 삼백초 추출물을포함하는 아토피성 피부질환의 경감 또는 치료용 조성물